Efficacy and Safety Profile of Fluticasone Furoate Administered Once Daily in the Morning or Evening: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial in Adult and Adolescent Patients With Persistent Bronchial Asthma

Clinical Therapeutics

Volumn 34, Issue 8, 2012, Pages 1683-1695

  Medley, Hilary ^a   Orozco, Socorro ^b   Allen, Ann ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

Author keywords

Asthma; Diskhaler; Fluticasone furoate; Inhaled corticosteroid; Rotadisk

Indexed keywords

FLUTICASONE FUROATE; HYDROCORTISONE; PLACEBO; ROTADISK DISKHALER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CANDIDIASIS; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; EVENING DOSAGE; FEMALE; FORCED EXPIRATORY VOLUME; HOARSENESS; HUMAN; HYDROCORTISONE URINE LEVEL; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OROPHARYNX CANDIDIASIS; PEAK EXPIRATORY FLOW; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCORING SYSTEM; THRUSH;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANDROSTADIENES; ASTHMA; BRONCHODILATOR AGENTS; CHILE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EQUIPMENT DESIGN; EUROPE; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; LUNG; MALE; MEXICO; MIDDLE AGED; MODELS, BIOLOGICAL; NEBULIZERS AND VAPORIZERS; PEAK EXPIRATORY FLOW RATE; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84864632347     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.06.024     Document Type: Article

References (26)

1. Guidelines for the Diagnosis and Management of Asthma (EPR-3) 2007. National Heart, Blood and Lung Institute, NIH publication no. 08-4051 August 2007, National Institutes of Health.
2. Global Strategy for Asthma Management and Prevention; December 2011 update Global Initiative for Asthma (GINA), Accessed July 8, 2012. http://www.ginasthma.com/.
3. Hermosa J.L., Sánchez C.B., Rubio M.C., et al. Factors associated with the control of severe asthma. J Asthma 2010, 47:124-130.
4. Gamble J., Stevenson M., McClean E., et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med 2009, 180:817-822.
5. Price D., Robertson A., Bullen K., et al. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med 2010, 10:1.
6. Sutherland E.R. Nocturnal asthma. J Allergy Clin Immunol 2005, 116:1179-1186.
7. Calhoun W.J. Nocturnal asthma. Chest 2003, 123(Suppl 3):399S-405S.
8. Jones A.H., Langdon C.G., Lee P.S., et al. Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. Respir Med 1994, 88:293-299.
9. Zetterström O., Dahl R., Lindqvist A., et al. Comparable morning versus evening administration of once-daily mometasone furoate dry powder inhaler. Respir Med 2008, 102:1406-1411.
10. Woodcock A., Bleecker E.R., Bateman E.D., et al. Efficacy in asthma of once daily treatment with fluticasone furoate: a randomized placebo controlled trial. Respir Res 2011, 12:132.
11. Postma D.S., Sevette C., Martinat Y., et al. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001, 17:1083-1088.
12. Noonan M., Karpel J.P., Bensch G.W., et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol 2001, 86:36-43.
13. Reinberg A., Smolensky M.H., D'Alonzo G.E., et al. Chronobiology and asthma III. Timing corticotherapy to biological rhythms to optimize treatment goals. J Asthma 1988, 25:219-248.
14. Kosoglou T., Cutler D.L., Staudinger H., Herron J.M. Once-daily evening dosing of mometasone furoate administered via a dry powder inhaler does not adversely affect the hypothalamic-pituitary-adrenal axis. Chest 2010, 137:115-121.
15. Meibohm B., Hochhaus G., Rohatagi S., et al. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol 1997, 37:704-710.
16. Busse W., Bleecker E.R., Bateman E.D., et al. Fluticasone furoate demonstrates efficacy in asthma patients symptomatic on medium doses of inhaled corticosteroid therapy: a randomised, placebo-controlled trial. Thorax 2012, 67:35-41.
17. Bateman E.D., Bleecker E.R., Busse W., et al. Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med 2012, 106:642-650.
18. Bleecker E.R., Bateman E.D., Busse W., et al. Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy. Eur Respir J 2010, 36(Suppl 54):204s.
19. Woodcock A., Bleecker E.R., Bateman E.D., et al. Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. Respir Res 2011, 12:160.
20. Bates D.M., Watts D.G. Nonlinear Regression Analysis and its Applications 1988, John Wiley & Sons Inc. N.J. Hoboken (Ed.).
21. Boeckman A.J., Sheiner L.B., Beal S.L. NONMEM Users Guide 1992 and 1998, NONMEM Project Group, San Francisco, CA.
22. Beal S.L. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001, 28:481-504.
23. Salter M., Biggadike K., Matthews J.L., et al. Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. Am J Physiol Lung Cell Mol Physiol 2007, 293:L660e7.
24. van den Berge M., Luijk B., Bareille P., et al. Prolonged protection of the new inhaled corticosteroid fluticasone furoate against AMP hyperresponsiveness in patients with mild asthma. Allergy 2010, 65:1531e5.
25. Ahmet A., Kim H., Spier S. Adrenal suppression: a practical guide to the screening and management of this under-recognized complication of inhaled corticosteroid therapy. Allergy Asthma Clin Immunol 2011, 7:13.
26. Greenfield J.R., Samaras K. Suppression of HPA axis in adults taking inhaled corticosteroids. Thorax 2006, 61:272-273.